# Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

> **NCT03912337** · PHASE4 · TERMINATED · sponsor: **Amgen** · enrollment: 29 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Placebo
- **DRUG:** Erenumab

## Key facts

- **NCT ID:** NCT03912337
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-04
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-07-28
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Terminated \[Study would not complete enrollment target until 2026 with results available in 2027. The information will not be useful at that time.\]
- **Last updated:** 2022-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912337, "Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03912337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*